Table 3 Effectiveness outcomes and measures of adverse consequences
Outcome category | Outcome measure | Definition |
|---|---|---|
Effectiveness | In-hospital mortality | Vital status at hospital discharge |
Discharge disposition | Binary variable for whether or not the patient was discharged to home | |
Duration of MV | Total number of hours from trial enrollment to extubation for at least 24 h | |
ICU length of stay | Total number of days from trial enrollment to discharge from study ICU | |
Hospital length of stay | Total number of days from trial enrollment to discharge from hospital | |
Adverse consequences | Life-threatening acidemia | Arterial or venous blood gas during MV with a pH of less than 7.10 |
Cumulative doses of sedative medications | Total doses of benzodiazepines, narcotics, or Propofol administered during MV as continuous infusions or bolus doses, calculated using dose equivalents in each class | |
Days with acute brain dysfunction | Total number of days from the time of enrollment until hospital discharge with at least one of the following: a positive delirium screen using the Confusion Assessment Method for the ICU (CAM-ICU) or a Richmond Agitation-Sedation Scale (RASS) score less than or equal to − 4 |